The awards ceremony was carried out under the auspices of the 8th conference of the Greek Association of Pharmacology.
On behalf of the conference's organising committee, a commemorative plaque was offered to Mr. Pentafragas, by the professors A. Papapetropoulos and E. Manolopoulos, who enthusiastically proclaimed the awardee's long-standing contribution and passion for the advancement of pharmaceutical research and innovation in Greece.
Mr. D. Pentafragas, the Founder of ELPEN, the leading Greek pharmaceutical company in Greece, has consumed with heartfelt zeal and commitment, 45 years of a life's work with the sole objective: to see his company grow, excel, to be an innovator, and above all else to graciously offer to our fellow man!
Today, ELPEN is considered an esteemed and important pioneer, a pillar of Greece's pharmaceutical industry. In terms of the company's participation in the country's development efforts, ELPEN:
- Manufactures qualitative and reliable pharmaceutical products whose production is based on internationally acknowledged manufacturing practices
- Maintains an active initiative in the exporting of its products in over 50 countries worldwide, while being a brilliant example of extrovert entrepreneurial spirit, and enjoying the merits of worldwide recognition and trust in Greek products
- Contributes substantially and decisively to the growth of the country's manufacturing industry
- Contributes to the development and support of the country's ailing sector of employment with continuous investments in infrastructure, in clinical research, and human resources
- Offers back to society by means of supporting extensive programs in the sector of Company Social Responsibility
In terms of research and innovation, our pioneering ELPEN Experimental and Research Center, the only one of its kind in Greece offering the largest private laboratory in the country, proudly enjoys national and international fame and honors. The prominent cardiologist, Sir Magdi Yacoub, upon visiting several times, proclaimed the Center to be "a fantastic, innovative, pioneering project". Having this body of work in the field of research allows for ELPEN to go up against any multinational: our company was the first pharmaceutical company in the world to receive marketing approval for the generic combination dry powder inhaler product prescribed for respiratory diseases!
In his acceptance speech, Mr. D. Pentafragas underlined that the innovative, patented, Elpenhaler® dry powder inhaler, prescribed for asthma and COPD, is a product which he personally invented, and is a patent holder in over 100 countries. He stressed the fact that the Elpenhaler® device will in fact pave the way for successful business endeavors so much for ELPEN, as much as for the Greek scientific world, and Greek exports, thus benefiting our country!